Microdosing and ADHD: what research says

Search online for "microdosing ADHD" and you'll find big promises. We'd rather give you something more useful: an honest map of what is known, what isn't, and what that means in practice.

The short answer: research has not shown that microdosing psilocybin helps with ADHD. Most studies are observational, placebo-controlled data specific to ADHD are scarce, and the most rigorous general studies found similar changes with a placebo. Microdosing is not a treatment, and ADHD care belongs with your doctor.

First, a clear position

ADHD is a neurodevelopmental condition, diagnosed and followed by health professionals. Microdosing psilocybin is not a treatment for ADHD, and our truffles are not designed, tested or sold to treat, relieve or prevent any condition. If you live with ADHD, your care belongs to you and your doctor. This article doesn't change that. The difference between microdosing and clinical psilocybin research is explained in microdosing is not therapy.

The curiosity, though, is real. It deserves a straight answer.

Why the topic keeps coming up

Adults with ADHD are well represented among people who say they microdose. In online communities and surveys, some describe feeling more focused, calmer or more organised on the days they take a microdose. Others notice nothing at all, or feel more restless. See also what a microdose can feel like.

These accounts are interesting. They are also exactly that: personal accounts. They can't tell us whether a change comes from psilocybin, from expectation, from the extra care people put into their routines when they start something new, or from all of the above.

What the research looks at

Observational studies

Most published work on microdosing and ADHD is observational. Researchers follow people who already microdose on their own and ask them, through questionnaires, how they feel over time. Some of these studies report that participants describe fewer difficulties with attention.

The limits matter:

• there is no placebo group to compare with;
• participants know what they are taking, and usually expect it to help;
• people with a disappointing experience tend to drop out, or never sign up;
• substances and doses vary widely and are rarely verified.

In short, these studies raise questions. They don't answer them. We look at the wider evidence in what research says about microdosing, and its limits.

Placebo-controlled trials

The more reliable method is the double-blind, placebo-controlled trial, where neither participants nor researchers know who received the active substance. In the general population, studies of this kind published in 2021 and 2022, including the self-blinding study led by Szigeti and colleagues, found that well-being often improved during microdosing periods, but roughly as much with placebo as with the active substance. Expectation, in other words, does a lot of the work.

For ADHD specifically, placebo-controlled trials are still rare. More research is under way. For now, the data remain preliminary and do not support any claim of efficacy.

How to read a study on microdosing and ADHD

When an article reports that microdosing "may help" with attention, a few questions show how much weight it can bear:

Question	Why it matters
Was ADHD diagnosed by a professional, or self-reported?	Self-identified traits and a clinical diagnosis are not the same population.
Who measured the change?	A participant's own rating is more open to expectation than a blinded assessment.
Was there a placebo group?	Without one, expectations can't be separated from the substance.
Were participants also on medication?	Other treatments and changes in routine can explain differences.
How many dropped out?	If people with poor experiences leave, the remaining results look better than they are.

If an article can't answer these questions, its conclusions are hypotheses at best.

Placebo, expectations and new routines

Starting something new usually comes with extra attention: planning the day, noting how you feel, going to bed a little earlier. That attention alone can change how people describe their days, whatever they took. It is one reason placebo groups often report changes too.

Expectations also run high around ADHD, where many people have tried numerous strategies and hope to find one that fits. That hope is understandable. It also makes self-observation harder to read, which is why notes kept over several weeks, including days without a dose, say more than a single good day.

What we deliberately don't say

You won't read here that microdosing "improves focus in ADHD", that it is "a natural alternative" to medication, or that it has "fewer side effects". None of that is established, and suggesting it would be misleading. Setting a microdose against a medical treatment is simply not an honest comparison.

If you're curious anyway

Adults make their own choices. A few principles we stand by:

• Talk to your doctor first. Especially if you take medication: how psilocybin interacts with ADHD medication, or with other treatments, is poorly studied. For one common case, see microdosing and antidepressants: interactions and precautions.
• Never stop or change a treatment on your own. Any change to your care is decided with the professional who follows you.
• Keep your expectations honest. Given what placebo studies show, "I feel a bit different" is hard for anyone to interpret.
• Keep notes. A simple journal of sleep, mood and energy makes for a factual conversation with your doctor. See keeping a microdosing journal.

Safety questions to discuss with your doctor

If you are thinking about microdosing while living with ADHD, these are the points to raise with the doctor who knows your situation:

• how psilocybin might interact with your current medication, since this has been little studied;
• any heart condition, or personal or family history of psychotic or bipolar disorders, which are reasons not to microdose;
• sleep, mood and anxiety, which some people say fluctuate on dose days;
• driving and work tasks that require full alertness.

Your doctor may not be able to give a definitive answer, because the research is thin. That uncertainty is itself useful information.

The bottom line

Research on microdosing and ADHD is young, small and mixed. It's worth following, and worth reading critically. What it doesn't justify today is any promise, whether from us or from anyone else. Other questions are answered in our frequently asked questions.

Important Microdosing is for adults only (18+). It is not recommended during pregnancy or breastfeeding, if you or a close family member have a history of psychotic or bipolar disorders, if you have a heart condition, or if you take any medication, especially antidepressants or lithium. Do not drive, do not combine with alcohol, and talk to a doctor first.

Psilocybin truffles are sold legally in the Netherlands, where BIEN is based. Their status varies from country to country: check the law in your country.

FAQ

Is it safe to microdose if you have ADHD?

Safety has not been established. Interactions with ADHD medication are poorly studied, and anyone with a health condition should talk to a doctor before considering it.

Can microdosing replace ADHD medication?

No. Microdosing is not a treatment, and nothing supports using it instead of prescribed care. Never stop or change a treatment on your own.

Is there research on microdosing and ADHD?

Yes, but it is limited: mostly observational studies of people who already microdose, and very few placebo-controlled trials. The data remain preliminary.

Can I take a microdose with ADHD medication?

That is a question for your doctor. Combinations have been little studied, which is a reason for caution rather than reassurance.

Sources

• Szigeti B. et al. (2021), Self-blinding citizen science to explore psychedelic microdosing, eLife.
• European Union Drugs Agency (EUDA): information on drugs in Europe.
• PubMed: studies on microdosing, database of the U.S. National Library of Medicine.